KR880002527A - 신경변질 치료용 안 조성물 - Google Patents

신경변질 치료용 안 조성물 Download PDF

Info

Publication number
KR880002527A
KR880002527A KR870009024A KR870009024A KR880002527A KR 880002527 A KR880002527 A KR 880002527A KR 870009024 A KR870009024 A KR 870009024A KR 870009024 A KR870009024 A KR 870009024A KR 880002527 A KR880002527 A KR 880002527A
Authority
KR
South Korea
Prior art keywords
composition
eye
tetraalkylpyrazine
neurodegeneration
treatment
Prior art date
Application number
KR870009024A
Other languages
English (en)
Inventor
시. 와이 치오우 죠오지
만-키트 람 도미닉
Original Assignee
원본미기재
휴스턴 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 휴스턴 바이오테크놀로지 인코포레이티드 filed Critical 원본미기재
Publication of KR880002527A publication Critical patent/KR880002527A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

신경변질 치료용 안 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 레이저도플러방법을 사용하여 측정된, 토끼의 망막 및 맥락막의 혈류에 대한 테트라메틸피라진 염산염(TMP), SMI(Tanshinones A1및 A2, Saliva miltiorrhiza injection)및 L-티모롤의 효과를 설명하는 챠아트,
제2도는 분리된 토끼의 심장에 대한 TMP의 효과를 설명하는 챠아트.
제3도는 여러가지 분리된 혈관에 대한 TMP의 효과를 설명하는 챠아트.

Claims (7)

  1. 망막 및 맥락막의 혈류를 향상시키기에 충분한 양내에, (1)8-16탄소원자로된 테트라알킬피라진 또는 눈 또는 시신경조직에 의해 흡수될 수 있는 형태로 생리학적으로 수용가능한 염 그리고 (2)안약용담체를 포함하는 안약용 조성물.
  2. 제1항에 있어서, 상기 테트라알킬피라진이 테트라메틸피라진인 것을 특징으로 하는 조성물.
  3. 제1항에 있어서, 상기 테트라알킬피라진이 무게로 약0.01∼5%에 존재하는 것을 특징으로 하는 조성물.
  4. 제1항에 따른 조성물의 효과적인 양을 포유동물의 숙주에 투여하는 것으로 이루어지는 눈의 혈류를 향상시키기 위한 방법.
  5. 제4항에 있어서, 상기 효과적인 양이 숙주의 0.5∼50mg/kg의 범위에 있는 것을 특징으로 하는 방법.
  6. 제4항에 있어서, 상기 투여가 고체인 눈 삽입물로 되는 것을 특징으로 하는 방법.
  7. 제4항에 있어서, 상기 투여가 국소적인 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870009024A 1986-08-18 1987-08-18 신경변질 치료용 안 조성물 KR880002527A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89774486A 1986-08-18 1986-08-18
US897744 1986-08-18

Publications (1)

Publication Number Publication Date
KR880002527A true KR880002527A (ko) 1988-05-09

Family

ID=25408350

Family Applications (2)

Application Number Title Priority Date Filing Date
KR870009024A KR880002527A (ko) 1986-08-18 1987-08-18 신경변질 치료용 안 조성물
KR870009025A KR880002519A (ko) 1986-08-18 1987-08-18 신경변질 치료용 안 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR870009025A KR880002519A (ko) 1986-08-18 1987-08-18 신경변질 치료용 안 조성물

Country Status (6)

Country Link
EP (2) EP0265042A3 (ko)
JP (2) JPS6399013A (ko)
KR (2) KR880002527A (ko)
AU (2) AU7671887A (ko)
DK (2) DK427387A (ko)
FI (2) FI873429A (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364884A (en) * 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2732896B1 (fr) * 1995-04-11 1997-06-13 Prographarm Lab Forme pharmaceutique transdermique pour l'administration percutanee de l'apomorphine
MXPA01011480A (es) * 1999-05-13 2002-06-04 Unihart Corp Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.
JP4306213B2 (ja) * 2002-09-30 2009-07-29 宇部興産株式会社 ６，７−メチレンジオキシクマリンの製造法
JP4175067B2 (ja) * 2002-09-30 2008-11-05 宇部興産株式会社 アルコキシアクリル酸アリールエステル誘導体、及びその製法
US20050054586A1 (en) * 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
JP2015519398A (ja) 2012-06-11 2015-07-09 マククリア・インコーポレイテッド 治療用製剤および処置の方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU506714B2 (en) * 1976-07-22 1980-01-24 Fisons Limited Bis benzopyram derivatives
US4189491A (en) * 1976-12-16 1980-02-19 Cuendet Jean Francois Tetrahydrocannabinol in a method of treating glaucoma
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤

Also Published As

Publication number Publication date
DK427287D0 (da) 1987-08-17
FI873429A (fi) 1988-02-19
JPS6399013A (ja) 1988-04-30
JPS6399010A (ja) 1988-04-30
FI873428A (fi) 1988-02-19
AU7676087A (en) 1988-02-25
EP0265042A3 (en) 1990-01-31
FI873428A0 (fi) 1987-08-06
EP0257887A3 (en) 1990-06-27
EP0265042A2 (en) 1988-04-27
EP0257887A2 (en) 1988-03-02
FI873429A0 (fi) 1987-08-06
DK427387A (da) 1988-02-19
AU7671887A (en) 1988-02-25
AU592006B2 (en) 1989-12-21
KR880002519A (ko) 1988-05-09
DK427387D0 (da) 1987-08-17
DK427287A (da) 1988-02-19

Similar Documents

Publication Publication Date Title
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR890011590A (ko) 안지오스타틴
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
NO875299L (no) Insulinpreparat for ikke-paranteral administrasjon.
KR890000101A (ko) 반월조직의 치료 개선방법 및 치료약제
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
KR920700649A (ko) 월경전기 증후군을 치료하는 방법
DK581685A (da) Transderimalt system for timolol-indgift
KR880002527A (ko) 신경변질 치료용 안 조성물
EP0045617A3 (en) Pharmaceutical composition
KR970025615A (ko) 암 전이 억제제
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR880013555A (ko) 당뇨병의 치료방법
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
Levy Studies on the Conditions of Activity in Endocrine Glands: IV. The effect of Thyroid Secretion on the Pressor Action of Adrenin
KR880007060A (ko) 제약 조성물
JPH08511024A (ja) 眼内圧を低下させる方法および組成物
KR910002442A (ko) 안구질환을 치료하는 방법 및 제약학적 조성물
KR880007068A (ko) 13-시스 레티노산의 용도
KR920003981A (ko) 항염증성 조성물
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR910019622A (ko) 안과용 상승적 병용으로 안고혈압의 치료
US5221690A (en) Increasing the choroidal blood flow

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid